Direct Inhibition of PI3K in Combination with Dual HER2 Inhibitors is Required for Optimal Antitumor Activity in HER2+ Breast Cancer Cells

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2014 Jan 24

PMID 24451154

Citations 51

Authors

Brent N Rexer

Siprachanh Chanthaphaychith

Kimberly Dahlman

Carlos L Arteaga

Affiliations

Soon will be listed here.

Abstract

Introduction: Despite multiple advances in the treatment of HER2+ breast cancers, resistance develops even to combinations of HER2 targeting agents. Inhibition of PI3K pathway signaling is critical for the efficacy of HER2 inhibitors. Activating mutations in PIK3CA can overlap with HER2 amplification and have been shown to confer resistance to HER2 inhibitors in preclinical studies.

Methods: Lapatinib-resistant cells were profiled for mutations in the PI3K pathway with the SNaPshot assay. Hotspot PIK3CA mutations were retrovirally transduced into HER2-amplified cells. The impact of PIK3CA mutations on the effect of HER2 and PI3K inhibitors was assayed by immunoblot, proliferation and apoptosis assays. Uncoupling of PI3K signaling from HER2 was investigated by ELISA for phosphoproteins in the HER2-PI3K signaling cascade. The combination of HER2 inhibitors with PI3K inhibition was studied in HER2-amplified xenograft models with wild-type or mutant PIK3CA.

Results: Here we describe the acquisition of a hotspot PIK3CA mutation in cells selected for resistance to the HER2 tyrosine kinase inhibitor lapatinib. We also show that the gain of function conferred by these PIK3CA mutations partially uncouples PI3K signaling from the HER2 receptor upstream. Drug resistance conferred by this uncoupling was overcome by blockade of PI3K with the pan-p110 inhibitor BKM120. In mice bearing HER2-amplified wild-type PIK3CA xenografts, dual HER2 targeting with trastuzumab and lapatinib resulted in tumor regression. The addition of a PI3K inhibitor further improved tumor regression and decreased tumor relapse after discontinuation of treatment. In a PIK3CA-mutant HER2+ xenograft, PI3K inhibition with BKM120 in combination with lapatinib and trastuzumab was required to achieve tumor regression.

Conclusion: These results suggest that the combination of PI3K inhibition with dual HER2 blockade is necessary to circumvent the resistance to HER2 inhibitors conferred by PIK3CA mutation and also provides benefit to HER2+ tumors with wild-type PIK3CA tumors.

Citing Articles

Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities.

Zhou Y, Chu J, Zhao S, Li G, Fu Z, Zhang S Acta Pharmacol Sin. 2024; 45(6):1287-1304.

PMID: 38360930 PMC: 11130324. DOI: 10.1038/s41401-024-01232-9.

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer.

Cataldo M, De Placido P, Esposito D, Formisano L, Arpino G, Giuliano M Front Oncol. 2023; 13:1108242.

PMID: 37469415 PMC: 10353540. DOI: 10.3389/fonc.2023.1108242.

Comparison of Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations.

Chen J, Murugesan K, Newberg J, Sokol E, Savage H, Stout T JCO Precis Oncol. 2022; 6:e2200341.

PMID: 36446041 PMC: 9812634. DOI: 10.1200/PO.22.00341.

Combined Docetaxel/Pictilisib-Loaded mPEGylated Nanocarriers with Dual HER2 Targeting Antibodies for Synergistic Chemotherapy of Breast Cancer.

Cheng W, Lin S, Chuang K, Chen M, Ho H, Chen L Int J Nanomedicine. 2022; 17:5353-5374.

PMID: 36419719 PMC: 9677924. DOI: 10.2147/IJN.S388066.

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer.

Elshazly A, Gewirtz D Cancer Drug Resist. 2022; 5(2):472-486.

PMID: 35800378 PMC: 9255238. DOI: 10.20517/cdr.2022.09.

References

Blackwell K, Burstein H, Storniolo A, Rugo H, Sledge G, Aktan G . Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012; 30(21):2585-92. DOI: 10.1200/JCO.2011.35.6725. View

Chakrabarty A, Rexer B, Wang S, Cook R, Engelman J, Arteaga C . H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene. 2010; 29(37):5193-203. PMC: 2945381. DOI: 10.1038/onc.2010.257. View

Amin D, Sergina N, Ahuja D, McMahon M, Blair J, Wang D . Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 2010; 2(16):16ra7. PMC: 3033659. DOI: 10.1126/scitranslmed.3000389. View

Isakoff S, Engelman J, Irie H, Luo J, Brachmann S, Pearline R . Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005; 65(23):10992-1000. DOI: 10.1158/0008-5472.CAN-05-2612. View

Garcia-Garcia C, Ibrahim Y, Serra V, Calvo M, Guzman M, Grueso J . Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res. 2012; 18(9):2603-12. DOI: 10.1158/1078-0432.CCR-11-2750. View

Hanker A, Pfefferle A, Balko J, Kuba M, Young C, Sanchez V . Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A. 2013; 110(35):14372-7. PMC: 3761610. DOI: 10.1073/pnas.1303204110. View

Junttila T, Akita R, Parsons K, Fields C, Lewis Phillips G, Friedman L . Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009; 15(5):429-40. DOI: 10.1016/j.ccr.2009.03.020. View

Baselga J, Cortes J, Im S, Clark E, Ross G, Kiermaier A . Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014; 32(33):3753-61. DOI: 10.1200/JCO.2013.54.5384. View

Holbro T, Beerli R, Maurer F, Koziczak M, Barbas 3rd C, Hynes N . The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003; 100(15):8933-8. PMC: 166416. DOI: 10.1073/pnas.1537685100. View

10.

Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C . Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012; 379(9816):633-40. PMC: 5705192. DOI: 10.1016/S0140-6736(11)61847-3. View

11.

Engelman J, Janne P, Mermel C, Pearlberg J, Mukohara T, Fleet C . ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A. 2005; 102(10):3788-93. PMC: 553328. DOI: 10.1073/pnas.0409773102. View

12.

Yarden Y, Sliwkowski M . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2):127-37. DOI: 10.1038/35052073. View

13.

Berns K, Horlings H, Hennessy B, Madiredjo M, Hijmans E, Beelen K . A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007; 12(4):395-402. DOI: 10.1016/j.ccr.2007.08.030. View

14.

Huang C, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu V, Kinzler K . The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science. 2007; 318(5857):1744-8. DOI: 10.1126/science.1150799. View

15.

Yakes F, Chinratanalab W, Ritter C, King W, Seelig S, Arteaga C . Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002; 62(14):4132-41. View

16.

OBrien C, Wallin J, Sampath D, GuhaThakurta D, Savage H, Punnoose E . Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010; 16(14):3670-83. DOI: 10.1158/1078-0432.CCR-09-2828. View

17.

Lovly C, Dahlman K, Fohn L, Su Z, Dias-Santagata D, Hicks D . Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One. 2012; 7(4):e35309. PMC: 3335021. DOI: 10.1371/journal.pone.0035309. View

18.

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

19.

Yao E, Zhou W, Lee-Hoeflich S, Truong T, Haverty P, Eastham-Anderson J . Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res. 2009; 15(12):4147-56. DOI: 10.1158/1078-0432.CCR-08-2814. View

20.

Brachmann S, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H . Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A. 2009; 106(52):22299-304. PMC: 2799764. DOI: 10.1073/pnas.0905152106. View